The Week of May 20 in Review

Biomarkers Still Needed in Prostate Cancer

Dr. Carey on Assays and Intrinsic Subtypes of Breast Cancer

Study of Inotuzumab Ozogamicin Halted After Interim Analysis

Mechanism of Action: Sorafenib

New Developments in Oral Targeted Agents for Advanced Colorectal Cancer

Dr. Cooperberg Comments on Earlier Prostate Cancer Treatment With Sipuleucel-T

FDA Grants Abraxane Priority Review for the Treatment of Pancreatic Cancer

Dr. Andre on Targets in Triple-Negative Breast Cancer

Treating Elderly Patients With CLL

Dr. McCarthy on Triplet Therapy for Multiple Myeloma

Although a variety of biomarkers have been shown to correlate with survival in men with prostate cancer, the use of biomarkers in the management of these patients may be dependent upon the clinical state and the class of drug evaluated.Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses assays and intrinsic subtypes of breast cancer.A phase III study of the investigational compound inotuzumab ozogamicin for patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who are not candidates for high-dose chemotherapy was halted after a scheduled interim analysis.Sorafenib is small molecule inhibitor approved for the treatment of primary kidney cancer and advanced primary liver cancer.Although progress has been made in treating colorectal cancer, including the development of biologic agents that target EGFR and angiogenesis, the median survival in mCRC remains about two years.Matthew Cooperberg, MD, MPH, Assistant Professor of Urology; Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, comments on treating men with prostate cancer earlier with sipuleucel-T (Provenge).The FDA has granted priority review to paclitaxel protein-bound particles for injectable suspension, albumin-bound, or nab-paclitaxel (Abraxane), as part of its supplemental new drug application for the first-line treatment of patients with metastatic pancreatic cancer when administered in combination with gemcitabine. http://www.targetedhc.com/articles/FDA-Grants-Abraxane-Priority-Review-for-the-Treatment-of-Pancreatic-CancerFabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche Médicale, Associate Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, gives an overview of targets in triple-negative breast cancer.Gentle yet effective therapies are called for when treating patients with chronic lymphocytic leukemia (CLL) who are age 65 years and older. While there is no standard treatment for most of those patients, several regimens are being tested in clinical trials.